A GLP-1 denial is rarely the end of the process. A prior authorization is a request for approval before the plan pays; a denial is a decision you can challenge, and the rules for challenging it are written down by regulators. For plans sold on the Marketplace, you generally have 180 days to file an internal appeal and 4 months to request an external review. For a Medicare Part D drug plan, the first appeal has to be filed within 65 days of the denial notice. The strongest appeals are usually the ones that show the plan how the request matches the FDA-approved indication, supported by a statement from your prescriber.
What a prior authorization actually is
Insurers use several tools to manage how a drug is covered: prior authorization (approval before the plan pays), step therapy (trying a different drug first), and quantity limits (a cap on what is dispensed in a given period). Medicare describes these as utilization management requirements, and in Part D the plan must decide whether you have met them as part of its coverage determination process.
For GLP-1 medicines, a prior authorization usually asks the prescriber to confirm that the drug is being used for an indication the plan covers. That is why it matters what the label actually says. The Wegovy prescribing information lists separate indications for the injection and the tablets, including weight reduction in adults with obesity or with overweight plus at least one weight-related condition, and cardiovascular risk reduction in adults with established cardiovascular disease. The Zepbound prescribing information lists weight reduction and moderate to severe obstructive sleep apnea in adults with obesity. The Foundayo prescribing information lists chronic weight management in adults with obesity, or overweight with at least one weight-related comorbid condition.
Those indications are the vocabulary of a prior authorization. A request that is framed around the labelled indication, with the supporting records attached, is easier for a reviewer to approve than one that is not.
Why a plan may say no
Denials tend to fall into a few groups, and identifying which one you have received decides what you do next.
| Type of denial | What it usually means | Typical next step |
|---|---|---|
| Not a covered benefit | The plan excludes the drug for this use altogether, for example by excluding weight-loss medicines. | Read your plan documents. An appeal is unlikely to change a plan-wide exclusion, but check whether another indication on the label applies to you. |
| Criteria not met | The plan says the records you sent do not show what its policy requires. | Ask what specific criterion was missed, then have the prescriber send the missing documentation. |
| Step therapy | The plan wants a different drug tried first. | Your prescriber can request an exception and explain in writing why the preferred drug is not appropriate. |
| Quantity limit | The plan limits the amount dispensed. | Ask the prescriber whether an exception is clinically justified. |
| Administrative | Missing form, wrong code, or an incomplete submission. | Often fixed by resubmitting, which is faster than an appeal. |
The first row matters more than people expect. The denial letter should state the reason, and the reason determines whether you are dealing with a paperwork problem or a coverage rule. Our overview of insurance coverage for oral GLP-1 medicines explains why coverage can differ between the injectable and tablet versions of the same active ingredient.
Step one: get the denial in writing and read it
Before you appeal anything, collect the denial notice. It should say why the request was denied and how to appeal. HealthCare.gov advises people appealing to include the denial notice, any explanation of benefits and any communications with the insurer, and to keep notes of phone calls including the date, time, the person’s name and title and a summary of the conversation. That record is worth far more than a memory of what you were told.
Check the date on the notice. Every deadline below runs from it.
Step two: the internal appeal
An internal appeal asks the insurer to reconsider its own decision. The rules depend on what kind of coverage you have.
Marketplace and many other private plans
According to HealthCare.gov, you must file an internal appeal within 180 days (6 months) of receiving notice that your claim was denied. For a standard appeal for a service you have not yet received, the insurer must complete it within 30 days; for a service already received, within 60 days. If the situation is urgent, the final decision must come as quickly as your medical condition requires and at least within 4 business days of the request.
Employer plans can be structured differently. Plans that are funded by the employer itself rather than bought from an insurer may follow federal rules that differ from state ones, and the denial letter or your benefits administrator is the place to confirm which process applies to you. Treat the HealthCare.gov figures as the Marketplace baseline, not a guarantee for every plan you could be on.
Medicare Part D
Part D uses different terms. The first decision is called a coverage determination, and it can be requested verbally or in writing by the enrollee, the prescriber or a representative. According to CMS, a standard request for a benefit must be decided within 72 hours and an expedited one within 24 hours, and for an exception request the clock starts only once the plan has the supporting statement from the prescriber.
If the answer is no, the first-level appeal is called a redetermination. CMS states the request must be filed within 65 calendar days of the notice of the coverage determination, and the plan must decide within 7 calendar days for a standard request or 72 hours for an expedited one. Medicare.gov notes that when you are asking for an exception, your prescriber must provide a statement explaining the medical reason why the exception should be approved.
Whether Medicare covers a GLP-1 for weight loss at all is a separate question that depends on the indication and the current rules; our guides on Medicare GLP-1 coverage and the Medicare GLP-1 bridge cover that ground.
What goes into a strong request
The prescriber carries most of the weight here, so it helps to know what to ask for. A request or appeal is easier to evaluate when it contains:
- The specific drug, strength and diagnosis, matched to the indication in the FDA label.
- Relevant measurements and history that the plan’s criteria ask about, such as body mass index, related conditions, and prior treatment, taken from the medical record rather than recalled.
- A prescriber statement explaining why this drug is appropriate for you, and, if step therapy is the issue, why the preferred alternative was unsuitable or has been tried.
- The denial notice and the reference numbers so the reviewer can match the appeal to the original decision.
What does not help is a long personal letter that does not address the stated reason for denial. The reviewer is checking the request against a policy. Answer the policy.
Fast tracks: when waiting is a problem
Both systems have an expedited path. On HealthCare.gov the urgent route is a decision as quickly as your condition requires, within 4 business days at the outside. In Part D the expedited timeframes are 24 hours for a coverage determination and 72 hours for a redetermination. These routes exist for situations where waiting could seriously jeopardise health, and your prescriber is the person who can say whether that standard is met. They are not a general way to speed up a routine request, and a plan can decide a request does not qualify.
Step three: external review
If the internal appeal fails on a Marketplace-type plan, you may be able to take the decision to an independent reviewer. HealthCare.gov says external review is available for denials that involve medical judgment, including a determination that a treatment is experimental or investigational. You must request it within 4 months of receiving the notice or final determination. A standard external review is decided no later than 45 days after the request, and an expedited one within 72 hours or less depending on medical urgency. The insurer is required by law to accept the external reviewer’s decision, and the cost to you cannot be more than $25 per external review for independent review organizations or state processes, with no charge for the HHS-administered process.
The point about medical judgment is important. A denial because the plan simply excludes a category of drug is not the same as a denial because the plan thinks the drug is not necessary for you, and only the second tends to fit the definition. If you are unsure which one you have, ask the plan or your state’s consumer assistance office to classify it.
In Medicare, the next step after a redetermination is reconsideration by an independent review entity. According to Medicare.gov, you have 60 days from the level 1 decision to file it, and the standard decision timeframe for a benefits appeal is 7 days, or 72 hours for a fast appeal.
A realistic order of operations
| # | Action | Who |
|---|---|---|
| 1 | Obtain the written denial and note the date and stated reason. | You |
| 2 | Ask whether the problem is paperwork, criteria, step therapy, quantity or a plan exclusion. | You or the prescriber’s office |
| 3 | Fix and resubmit if it is administrative. | Prescriber’s office |
| 4 | Otherwise file the internal appeal or redetermination before the deadline, with a prescriber statement. | You and the prescriber |
| 5 | If still denied and eligible, request external review or reconsideration. | You |
What if the answer stays no?
Sometimes it does. At that point the question becomes what other routes exist, and none of them is a quick fix. Your prescriber may consider a different FDA-approved medicine that your plan does cover. You can compare the cost of paying outside insurance, which our guide to the real cost of GLP-1 treatment walks through, noting that prices change and should be checked on the manufacturer’s own page. And you should be cautious about anyone who responds to a denial by offering a cheaper product of uncertain origin; our explainer on compounded semaglutide versus Wegovy sets out what actually differs and why it matters.
We have deliberately left prices out of this article. Coverage rules, not list prices, determine what a denial costs you, and the figures that matter are in your own plan documents.
Common mistakes
- Missing the deadline. The 65-day and 180-day clocks run from the notice date, not from when you opened the letter or when the pharmacy told you.
- Appealing the wrong thing. If the denial was administrative, a resubmission is faster.
- Relying on phone calls with no record. Note who you spoke to and when.
- Leaving it all to the prescriber’s office. They are busy; a short follow-up with the reference number helps.
- Treating the first no as final. Many denials are reviewable, and the existence of an appeals ladder is the reason.
Questions people ask
Can my prescriber appeal for me?
In Part D, the enrollee, the prescriber or a representative may request a coverage determination, and Medicare.gov says the prescriber, you or your representative can ask for the first-level appeal. For other plans, check the denial letter for who may file.
Does a denial mean the drug is unsafe for me?
No. A denial is an insurance decision about coverage rules. Whether a medicine is right for you is a clinical question for your prescriber.
Is an exception the same as an appeal?
No. An exception asks the plan to cover a drug outside its usual rules, and it needs a prescriber statement. An appeal asks the plan to reverse a decision it has already made. In Part D they can overlap, which is why the prescriber statement matters in both.
Sources
- HealthCare.gov, Internal appeals, checked 5 October 2026.
- HealthCare.gov, External review, checked 5 October 2026.
- CMS, Part D coverage determinations, checked 5 October 2026.
- CMS, Redetermination by the Part D plan sponsor, checked 5 October 2026.
- Medicare.gov, Drug plan appeals, level 1, and appeals in a Medicare drug plan, checked 5 October 2026.
- U.S. FDA labeling: Wegovy, Zepbound, Foundayo prescribing information, indications and usage sections, checked 5 October 2026.
Medical disclaimer. This article is informational and is not medical, legal or insurance advice. Appeal rights and deadlines vary by plan and state, and the figures above come from the federal pages cited. Confirm the process in your own denial letter, and talk to your prescriber about treatment decisions.
Keep exploring our GLP-1 resources:
